Switch theme
Sign up to access all valuation multiples
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines.
2000
1.9K+
LTM Revenue $189M
LTM EBITDA $34.8M
$316M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Duopharma Biotech has a last 12-month revenue of $189M and a last 12-month EBITDA of $34.8M.
In the most recent fiscal year, Duopharma Biotech achieved revenue of $184M and an EBITDA of $34.3M.
Duopharma Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Duopharma Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $159M | $184M | XXX | XXX | XXX |
| Gross Profit | $63.1M | $60.5M | XXX | XXX | XXX |
| Gross Margin | 40% | 33% | XXX | XXX | XXX |
| EBITDA | $28.0M | $34.3M | XXX | XXX | XXX |
| EBITDA Margin | 18% | 19% | XXX | XXX | XXX |
| Net Profit | $15.8M | $11.9M | XXX | XXX | XXX |
| Net Margin | 10% | 6% | XXX | XXX | XXX |
| Net Debt | $61.2M | $62.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, Duopharma Biotech's stock price is MYR 1 (or $0).
Duopharma Biotech has current market cap of MYR 1.2B (or $260M), and EV of MYR 1.4B (or $316M).
See Duopharma Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $316M | $260M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, Duopharma Biotech has market cap of $260M and EV of $316M.
Duopharma Biotech's trades at 1.7x LTM EV/Revenue multiple, and 9.1x LTM EBITDA.
Analysts estimate Duopharma Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Duopharma Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $316M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.2x | XXX | XXX | XXX |
| P/E | 18.4x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 28.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDuopharma Biotech's NTM/LTM revenue growth is 9%
Duopharma Biotech's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $23K for the same period.
Over next 12 months, Duopharma Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Duopharma Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Duopharma Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 28% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $23K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 25% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Duopharma Biotech acquired XXX companies to date.
Last acquisition by Duopharma Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Duopharma Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Duopharma Biotech founded? | Duopharma Biotech was founded in 2000. |
| Where is Duopharma Biotech headquartered? | Duopharma Biotech is headquartered in Malaysia. |
| How many employees does Duopharma Biotech have? | As of today, Duopharma Biotech has 1.9K+ employees. |
| Is Duopharma Biotech publicy listed? | Yes, Duopharma Biotech is a public company listed on KLS. |
| What is the stock symbol of Duopharma Biotech? | Duopharma Biotech trades under 7148 ticker. |
| When did Duopharma Biotech go public? | Duopharma Biotech went public in 2002. |
| Who are competitors of Duopharma Biotech? | Similar companies to Duopharma Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Duopharma Biotech? | Duopharma Biotech's current market cap is $260M |
| What is the current revenue of Duopharma Biotech? | Duopharma Biotech's last 12-month revenue is $189M. |
| What is the current EBITDA of Duopharma Biotech? | Duopharma Biotech's last 12-month EBITDA is $34.8M. |
| What is the current EV/Revenue multiple of Duopharma Biotech? | Current revenue multiple of Duopharma Biotech is 1.7x. |
| What is the current EV/EBITDA multiple of Duopharma Biotech? | Current EBITDA multiple of Duopharma Biotech is 9.1x. |
| What is the current revenue growth of Duopharma Biotech? | Duopharma Biotech revenue growth between 2023 and 2024 was 15%. |
| Is Duopharma Biotech profitable? | Yes, Duopharma Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
